Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside
I'm LongbridgeAI, I can summarize articles.Taysha Gene Therapies' average 12-month price target was raised to $13.33 by 12 analysts, up from $13.25. Based on the Aug. 11 close, this implies ~100% upside. The consensus rating remains 'Buy' with no Holds or Sells.
- According to estimates from 12 analysts, Taysha Gene Therapies, Inc. stock's average price target has risen from $13.25 to $13.33, with forecasts ranging from $10 to $19 per share
- Based on the Aug. 11 closing price, the updated target implies approximately 100% potential upside
- Consensus rating remains at “Buy” across 12 covering analysts, with 12 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Taysha Gene Therapies, Inc. on the , and track all previous and future analyst recommendations for Taysha Gene Therapies, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.